Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lexicon

“A fantastic blend of features, portability, and audio quality that will serve many users well in crafting great-sounding mixes”: Soundcraft Notepad-12FX review

Compact, powerful, and versatile - but is the Soundcraft Notepad-12FX the best option for small studios?

This Guy Has Named More Products Than You Can Count

This Guy Has Named More Products Than You Can Count

David Placek's Lexicon Branding has cooked up some of the most-known brands.

Investors Business Daily

How to choose the right type of reverb for your mix

How to choose the right type of reverb for your mix

GEAR EXPO 2024: A dash of reverb can make or break the sound of your mix, so careful selection is key for getting the right spatial qualities

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

How to choose the right reverb for your mix

A dash of reverb can make or break the sound of your mix so careful selection is key for getting the right spatial qualities

Black Corporation's Expander Mk2 is all the vintage effects processing you'll ever need

Spanning analogue processing and faithful recreations of classic digital effects, this tabletop multi-effects powerhouse (pretty much) does it all

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Lexicon Shares Jump 20 Percent Following Positive Results From Mid-Stage Diabetic Neuropathy Study

Lexicon Pharmaceuticals (NASDAQ: LXRX) reported positive topline results from the Phase 2 proof-of-concept study of its lead candidate LX9211 in painful diabetic neuropathy. The RELIEF-DPN-1 is the first of two Phase 2 proof-of-concept study designed to evaluate LX9211 in patients with neuropathic pain.

inkl

Read news from The Economist, FT, and more,
with one subscription

Lexicon Touts New Favorable Data On Sotaglifozin Cardio Data

Lexicon Touts New Favorable Data On Sotaglifozin Cardio Data

At the American College of Cardiology, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) highlighted a new data analysis from the SCORED Phase 3 trial of sotagliflozin in Type 2 diabetes and kidney disease patients. Sotagliflozin significantly reduced major adverse cardiovascular events (MACE) of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke compared to placebo. Also See: Lexicon Announces…

Lexicon Announces Loan Facility Of $150M With Oxford Finance To Support Sotagliflozin Commercialization

Lexicon Announces Loan Facility Of $150M With Oxford Finance To Support Sotagliflozin Commercialization

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) entered into a loan facility with Oxford Finance LLC for $150 million to support commercial preparations and the potential launch of sotagliflozin in heart failure. The loan facility consists of four tranches, each maturing in March 2027. An initial $25 million tranche was funded at closing. The second $25 million tranche…

The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill

The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill

Here's a roundup of top developments in the biotech space over the last 24 hours.

Lexicon Pharma Pulls Sotagliflozin US Application Due To Technical Issue, Shares Fall

Lexicon Pharma Pulls Sotagliflozin US Application Due To Technical Issue, Shares Fall

Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) has

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Intel Corporation

Food and Drug Administration

European Medicines Agency

US Food and Drug Administration

Impossible Foods

IDEAYA Biosciences

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

243,713 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play